291 related articles for article (PubMed ID: 29383666)
1. Clostridium difficile Biofilm.
Vuotto C; Donelli G; Buckley A; Chilton C
Adv Exp Med Biol; 2018; 1050():97-115. PubMed ID: 29383666
[TBL] [Abstract][Full Text] [Related]
2. Clostridioides difficile Biofilm.
Vuotto C; Donelli G; Buckley A; Chilton C
Adv Exp Med Biol; 2024; 1435():249-272. PubMed ID: 38175479
[TBL] [Abstract][Full Text] [Related]
3. High sporulation and overexpression of virulence factors in biofilms and reduced susceptibility to vancomycin and linezolid in recurrent Clostridium [Clostridioides] difficile infection isolates.
Tijerina-Rodríguez L; Villarreal-Treviño L; Baines SD; Morfín-Otero R; Camacho-Ortíz A; Flores-Treviño S; Maldonado-Garza H; Rodríguez-Noriega E; Garza-González E
PLoS One; 2019; 14(7):e0220671. PubMed ID: 31365590
[TBL] [Abstract][Full Text] [Related]
4. Subinhibitory concentrations of metronidazole increase biofilm formation in Clostridium difficile strains.
Vuotto C; Moura I; Barbanti F; Donelli G; Spigaglia P
Pathog Dis; 2016 Mar; 74(2):. PubMed ID: 26656887
[TBL] [Abstract][Full Text] [Related]
5. Outcome of relapsing Clostridium difficile infections do not correlate with virulence-, spore- and vegetative cell-associated phenotypes.
Plaza-Garrido Á; Miranda-Cárdenas C; Castro-Córdova P; Olguín-Araneda V; Cofré-Araneda G; Hernández-Rocha C; Carman R; Ibáñez P; Fawley WN; Wilcox MH; Gil F; Calderón IL; Fuentes JA; Guzmán-Durán AM; Alvarez-Lobos M; Paredes-Sabja D
Anaerobe; 2015 Dec; 36():30-8. PubMed ID: 26403333
[TBL] [Abstract][Full Text] [Related]
6. Biofilm formation by Clostridium difficile.
Dapa T; Unnikrishnan M
Gut Microbes; 2013; 4(5):397-402. PubMed ID: 23892245
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial effects of Manuka honey on in vitro biofilm formation by Clostridium difficile.
Piotrowski M; Karpiński P; Pituch H; van Belkum A; Obuch-Woszczatyński P
Eur J Clin Microbiol Infect Dis; 2017 Sep; 36(9):1661-1664. PubMed ID: 28417271
[TBL] [Abstract][Full Text] [Related]
8. Multiple factors modulate biofilm formation by the anaerobic pathogen Clostridium difficile.
Ðapa T; Leuzzi R; Ng YK; Baban ST; Adamo R; Kuehne SA; Scarselli M; Minton NP; Serruto D; Unnikrishnan M
J Bacteriol; 2013 Feb; 195(3):545-55. PubMed ID: 23175653
[TBL] [Abstract][Full Text] [Related]
9. Antibiotic Resistances of Clostridium difficile.
Spigaglia P; Mastrantonio P; Barbanti F
Adv Exp Med Biol; 2018; 1050():137-159. PubMed ID: 29383668
[TBL] [Abstract][Full Text] [Related]
10. Comparison of planktonic and biofilm-associated communities of Clostridium difficile and indigenous gut microbiota in a triple-stage chemostat gut model.
Crowther GS; Chilton CH; Todhunter SL; Nicholson S; Freeman J; Baines SD; Wilcox MH
J Antimicrob Chemother; 2014 Aug; 69(8):2137-47. PubMed ID: 24788662
[TBL] [Abstract][Full Text] [Related]
11. A combination of the probiotic and prebiotic product can prevent the germination of Clostridium difficile spores and infection.
Rätsep M; Kõljalg S; Sepp E; Smidt I; Truusalu K; Songisepp E; Stsepetova J; Naaber P; Mikelsaar RH; Mikelsaar M
Anaerobe; 2017 Oct; 47():94-103. PubMed ID: 28465256
[TBL] [Abstract][Full Text] [Related]
12. Clostridium difficile recurrent infection: possible implication of TA systems.
Gil F; Pizarro-Guajardo M; Álvarez R; Garavaglia M; Paredes-Sabja D
Future Microbiol; 2015; 10(10):1649-57. PubMed ID: 26439907
[TBL] [Abstract][Full Text] [Related]
13. Type IV pili promote early biofilm formation by Clostridium difficile.
Maldarelli GA; Piepenbrink KH; Scott AJ; Freiberg JA; Song Y; Achermann Y; Ernst RK; Shirtliff ME; Sundberg EJ; Donnenberg MS; von Rosenvinge EC
Pathog Dis; 2016 Aug; 74(6):. PubMed ID: 27369898
[TBL] [Abstract][Full Text] [Related]
14. Nonantimicrobial drug targets for Clostridium difficile infections.
Darkoh C; Deaton M; DuPont HL
Future Microbiol; 2017 Sep; 12(11):975-985. PubMed ID: 28759258
[TBL] [Abstract][Full Text] [Related]
15. Impact of microbial derived secondary bile acids on colonization resistance against Clostridium difficile in the gastrointestinal tract.
Winston JA; Theriot CM
Anaerobe; 2016 Oct; 41():44-50. PubMed ID: 27163871
[TBL] [Abstract][Full Text] [Related]
16. Recurrence of dual-strain Clostridium difficile infection in an in vitro human gut model.
Crowther GS; Chilton CH; Todhunter SL; Nicholson S; Freeman J; Wilcox MH
J Antimicrob Chemother; 2015 Aug; 70(8):2316-21. PubMed ID: 25925596
[TBL] [Abstract][Full Text] [Related]
17. Acyldepsipeptide antibiotics as a potential therapeutic agent against Clostridium difficile recurrent infections.
Gil F; Paredes-Sabja D
Future Microbiol; 2016 Sep; 11():1179-89. PubMed ID: 27546386
[TBL] [Abstract][Full Text] [Related]
18. Update on Antimicrobial Resistance in Clostridium difficile: Resistance Mechanisms and Antimicrobial Susceptibility Testing.
Peng Z; Jin D; Kim HB; Stratton CW; Wu B; Tang YW; Sun X
J Clin Microbiol; 2017 Jul; 55(7):1998-2008. PubMed ID: 28404671
[TBL] [Abstract][Full Text] [Related]
19. Non-conventional antimicrobial and alternative therapies for the treatment of Clostridium difficile infection.
Roshan N; Hammer KA; Riley TV
Anaerobe; 2018 Feb; 49():103-111. PubMed ID: 29309845
[TBL] [Abstract][Full Text] [Related]
20. An In Vitro Model of the Human Colon: Studies of Intestinal Biofilms and Clostridium difficile Infection.
Crowther GS; Wilcox MH; Chilton CH
Methods Mol Biol; 2016; 1476():223-34. PubMed ID: 27507345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
